Innovations in the Quantitative Virus Outgrowth Assay and Its Use in Clinical Trials

Overview

Journal Retrovirology

Publisher Biomed Central

Specialty Microbiology

Date 2017 Dec 23

PMID 29268753

Citations 6

Authors

Nicholas J Norton

Axel Fun

Mikaila Bandara

Mark R Wills

Hoi Ping Mok

Andrew M L Lever

Affiliations

Soon will be listed here.

Abstract

A robust measure of the size of the latent HIV reservoir is essential to quantifying the effect of interventions designed to deplete the pool of reactivatable, replication competent proviruses. In addition to the ability to measure a biologically relevant parameter, any assay designed to be used in a clinical trial needs to be reproducible and scalable. The need to quantify the number of resting CD4+ T cells capable of releasing infectious virus has led to the development of the quantitative viral outgrowth assay (VOA). The assay as originally described has a number of features that limit its scalability for use in clinical trials; however recent developments reducing the time and manpower requirements of the assay, while importantly improving reproducibility mean that it is becoming much more practical for it to enter into more widespread use. This review describes the background to VOA development and the practical issues that they present in utilising them in clinical trials. It describes the innovations that have made their usage more practical and the limitations that still exist.

Citing Articles

Ex Vivo Differentiation of Resting CD4+ T Lymphocytes Enhances Detection of Replication Competent HIV-1 in Viral Outgrowth Assays.

Wonderlich E, Reece M, Kulpa D Methods Mol Biol. 2022; 2407:315-331.

PMID: 34985673 DOI: 10.1007/978-1-0716-1871-4_21.

Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA.

Lungu C, Procopio F, Overmars R, Beerkens R, Voermans J, Rao S Viruses. 2020; 12(9).

PMID: 32887284 PMC: 7552071. DOI: 10.3390/v12090973.

Key Players in HIV-1 Transcriptional Regulation: Targets for a Functional Cure.

Mori L, Valente S Viruses. 2020; 12(5).

PMID: 32403278 PMC: 7291152. DOI: 10.3390/v12050529.

What's Hot in HIV in 2019-A Basic and Translational Science Summary for Clinicians From IDWeek 2019.

Titanji B, Kelley C Open Forum Infect Dis. 2020; 7(3):ofaa053.

PMID: 32154324 PMC: 7052744. DOI: 10.1093/ofid/ofaa053.

Effector memory differentiation increases detection of replication-competent HIV-l in resting CD4+ T cells from virally suppressed individuals.

Wonderlich E, Subramanian K, Cox B, Wiegand A, Lackman-Smith C, Bale M PLoS Pathog. 2019; 15(10):e1008074.

PMID: 31609991 PMC: 6812841. DOI: 10.1371/journal.ppat.1008074.

References

Spivak A, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus N . A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis. 2013; 58(6):883-90. PMC: 3935499. DOI: 10.1093/cid/cit813. View

Laird G, Eisele E, Rabi S, Lai J, Chioma S, Blankson J . Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 2013; 9(5):e1003398. PMC: 3667757. DOI: 10.1371/journal.ppat.1003398. View

Rasmussen T, Tolstrup M, Brinkmann C, Olesen R, Erikstrup C, Solomon A . Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2015; 1(1):e13-21. DOI: 10.1016/S2352-3018(14)70014-1. View

Schenkel J, Masopust D . Tissue-resident memory T cells. Immunity. 2014; 41(6):886-97. PMC: 4276131. DOI: 10.1016/j.immuni.2014.12.007. View

Procopio F, Fromentin R, Kulpa D, Brehm J, Bebin A, Strain M . A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine. 2015; 2(8):874-83. PMC: 4563128. DOI: 10.1016/j.ebiom.2015.06.019. View

Archin N, Bateson R, Tripathy M, Crooks A, Yang K, Dahl N . HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis. 2014; 210(5):728-35. PMC: 4148603. DOI: 10.1093/infdis/jiu155. View

Vibholm L, Schleimann M, Hojen J, Benfield T, Offersen R, Rasmussen K . Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. Clin Infect Dis. 2017; 64(12):1686-1695. PMC: 5849129. DOI: 10.1093/cid/cix201. View

Fun A, Mok H, Wills M, Lever A . A highly reproducible quantitative viral outgrowth assay for the measurement of the replication-competent latent HIV-1 reservoir. Sci Rep. 2017; 7:43231. PMC: 5324126. DOI: 10.1038/srep43231. View

Anderson J, Archin N, Ince W, Parker D, Wiegand A, Coffin J . Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol. 2011; 85(10):5220-3. PMC: 3126162. DOI: 10.1128/JVI.00284-11. View

10.

Archin N, Liberty A, Kashuba A, Choudhary S, Kuruc J, Crooks A . Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012; 487(7408):482-5. PMC: 3704185. DOI: 10.1038/nature11286. View

11.

Ho Y, Shan L, Hosmane N, Wang J, Laskey S, Rosenbloom D . Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013; 155(3):540-51. PMC: 3896327. DOI: 10.1016/j.cell.2013.09.020. View

12.

Archin N, Eron J, Palmer S, Hartmann-Duff A, Martinson J, Wiegand A . Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS. 2008; 22(10):1131-5. PMC: 3863687. DOI: 10.1097/QAD.0b013e3282fd6df4. View

13.

Rissin D, Kan C, Campbell T, Howes S, Fournier D, Song L . Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010; 28(6):595-9. PMC: 2919230. DOI: 10.1038/nbt.1641. View

14.

Chun T, Carruth L, Finzi D, Shen X, DiGiuseppe J, Taylor H . Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997; 387(6629):183-8. DOI: 10.1038/387183a0. View

15.

Archin N, Kirchherr J, Sung J, Clutton G, Sholtis K, Xu Y . Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. J Clin Invest. 2017; 127(8):3126-3135. PMC: 5531421. DOI: 10.1172/JCI92684. View

16.

Hosmane N, Kwon K, Bruner K, Capoferri A, Beg S, Rosenbloom D . Proliferation of latently infected CD4 T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. J Exp Med. 2017; 214(4):959-972. PMC: 5379987. DOI: 10.1084/jem.20170193. View

17.

Sanyal A, Mailliard R, Rinaldo C, Ratner D, Ding M, Chen Y . Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4 T cells. Nat Med. 2017; 23(7):885-889. PMC: 5505781. DOI: 10.1038/nm.4347. View

18.

Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C . Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5. DOI: 10.1126/science.278.5341.1291. View

19.

Brennan T, Woods J, Sedaghat A, Siliciano J, Siliciano R, Wilke C . Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol. 2009; 83(17):8470-81. PMC: 2738142. DOI: 10.1128/JVI.02568-08. View

20.

Myers L, McQuay L, Hollinger F . Dilution assay statistics. J Clin Microbiol. 1994; 32(3):732-9. PMC: 263116. DOI: 10.1128/jcm.32.3.732-739.1994. View